N Engl J Med · 2015

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR.

Show affiliations
  • Brahmer JFrom the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.B.); the City of Hope Comprehensive Cancer Center, Duarte, CA (K.L.R.); the Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam (P.B.), Erasmus MC Cancer Institute, Rotterdam (J.G.A.), and Ziekenhuis Amphia, Breda (J.G.A.) - all in the Netherlands; the University Hospital of Perugia, Perugia (L.C.), and the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (M.C.G.) - both in Italy; the Department of Medical Oncology, West German Cancer Center, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen (W.E.E.E.), the Thoraxklinik, Heidelberg University Hospital, Heidelberg (M.S.), and the LungenClinic Grosshansdorf, Grosshansdorf (M.R.) - all in Germany; the N.N. Blokhin Russian Cancer Research Center, Moscow (E.P.); the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (S.A.); the Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland (A.P.); the University of Chicago Medicine and Biological Sciences, Chicago (E.E.V.); the Hospital Madrid Norte Sanchinarro (E.H.), the Hospital Universitario Fundación Jiménez Díaz, Madrid (M.D.), and the Hospital Universitario Virgen Del Rocío, Seville (L.P.-A.) - all in Spain; Oncology Hematology Care, Cincinnati (D.W.); the Duke University Medical Center, Durham, NC (N.R.); Massachusetts General Hospital, Boston (J.G.); Centro Internacional de Estudios Clinicos, Santiago, Chile (O.A.F.); Nemocnice Na Bulovce, Prague, Czech Republic (L.H.); Bristol-Myers Squibb, Princeton, NJ (C.B., C.T.H., B.L.); and the Sarah Cannon Research Institute and Tennessee Oncology, Nashville (D.R.S.).
26 read7 want to readRigor 3.0Novelty 2.8Impact 2.6Reprod. 3.8

Most-cited papers citing this

  • Nature · 2026 · cited by 3
  • Curr Pharm Des · 2026 · cited by 3
  • J Hematol Oncol · 2025 · cited by 3
  • J Clin Oncol · 2026 · cited by 2
  • Cancer Cytopathol · 2026 · cited by 1

Log in to like, log, and share thoughts on this paper.

Discussion

Share your thoughts above to start a thread. Constructive feedback only — reply to and like others’ posts.

0

Sam Sato

Rigor 3/5Novelty 2/5Impact 1/5Reprod. 4/5

Solid methods, convincing results.

0

Ravi Rossi

Rigor 4/5Novelty 1/5Impact 1/5Reprod. 5/5

Great figures and clear story.

0

Omar Garcia

Rigor 5/5Novelty 1/5Impact 1/5Reprod. 4/5

Interesting idea, small sample.

0

Noor Wang

Rigor 2/5Novelty 4/5Impact 3/5Reprod. 5/5

Nice but incremental.

0

Ines Sato

Rigor 5/5Novelty 1/5Impact 5/5Reprod. 1/5

Solid methods, convincing results.

0

Sam Silva

Rigor 3/5Novelty 4/5Impact 1/5Reprod. 2/5

Great figures and clear story.

0

Ravi Smith

Rigor 5/5Novelty 4/5Impact 2/5Reprod. 5/5

Solid methods, convincing results.

0

Omar Silva

Rigor 3/5Novelty 3/5Impact 2/5Reprod. 5/5

Great figures and clear story.

0

Noor Nguyen

Rigor 2/5Novelty 5/5Impact 5/5Reprod. 3/5

Interesting idea, small sample.

0

Liam Kim

Rigor 3/5Novelty 1/5Impact 2/5Reprod. 4/5

Replication is unclear to me.

0

Yuki Patel

Rigor 5/5Novelty 2/5Impact 2/5Reprod. 4/5

Great figures and clear story.